204 related articles for article (PubMed ID: 24415413)
1. Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.
Suspitsin EN; Yanus GA; Sokolenko AP; Yatsuk OS; Zaitseva OA; Bessonov AA; Ivantsov AO; Heinstein VA; Klimashevskiy VF; Togo AV; Imyanitov EN
Med Oncol; 2014 Feb; 31(2):828. PubMed ID: 24415413
[TBL] [Abstract][Full Text] [Related]
2. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
[TBL] [Abstract][Full Text] [Related]
3. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
[TBL] [Abstract][Full Text] [Related]
4. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
5. Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients.
Sokolenko AP; Preobrazhenskaya EV; Aleksakhina SN; Iyevleva AG; Mitiushkina NV; Zaitseva OA; Yatsuk OS; Tiurin VI; Strelkova TN; Togo AV; Imyanitov EN
Cancer Lett; 2015 Apr; 359(2):259-61. PubMed ID: 25619955
[TBL] [Abstract][Full Text] [Related]
6. An inherited NBN mutation is associated with poor prognosis prostate cancer.
Cybulski C; Wokołorczyk D; Kluźniak W; Jakubowska A; Górski B; Gronwald J; Huzarski T; Kashyap A; Byrski T; Dębniak T; Gołąb A; Gliniewicz B; Sikorski A; Switała J; Borkowski T; Borkowski A; Antczak A; Wojnar L; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała P; Narod SA; Lubiński J;
Br J Cancer; 2013 Feb; 108(2):461-8. PubMed ID: 23149842
[TBL] [Abstract][Full Text] [Related]
7. Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability.
Iyevleva AG; Aleksakhina SN; Sokolenko AP; Baskina SV; Venina AR; Anisimova EI; Bizin IV; Ivantsov AO; Belysheva YV; Chernyakova AP; Togo AV; Imyanitov EN
Breast Cancer Res Treat; 2022 Apr; 192(2):283-291. PubMed ID: 35020107
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
Smid M; Schmidt MK; Prager-van der Smissen WJC; Ruigrok-Ritstier K; Schreurs MAC; Cornelissen S; Garcia AM; Broeks A; Timmermans AM; Trapman-Jansen AMAC; Collée JM; Adank MA; Hooning MJ; Martens JWM; Hollestelle A
Breast Cancer Res; 2023 May; 25(1):53. PubMed ID: 37161532
[TBL] [Abstract][Full Text] [Related]
9. A common nonsense mutation of the BLM gene and prostate cancer risk and survival.
Antczak A; Kluźniak W; Wokołorczyk D; Kashyap A; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Masojć B; Górski B; Gromowski T; Nagorna A; Gołąb A; Sikorski A; Słojewski M; Gliniewicz B; Borkowski T; Borkowski A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Domagała P; Stawicka M; Milecki P; Akbari MR; Narod SA; Lubiński J; Cybulski C; ; ; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała W; Chosia M; van de Wetering T; Serrano-Fernández P; Puszyński M; Soczawa M; Switała J; Archimowicz S; Kordowski M; Zyczkowski M; Borówka A; Bagińska J; Krajka K; Szwiec M; Haus O; Janiszewska H; Stembalska A; Sąsiadek MM
Gene; 2013 Dec; 532(2):173-6. PubMed ID: 24096176
[TBL] [Abstract][Full Text] [Related]
10. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.
Pfeifer W; Sokolenko AP; Potapova ON; Bessonov AA; Ivantsov AO; Laptiev SA; Zaitseva OA; Yatsuk OS; Matsko DE; Semiglazova TY; Togo AV; Imyanitov EN
Breast Cancer Res Treat; 2014 Dec; 148(3):675-83. PubMed ID: 25414026
[TBL] [Abstract][Full Text] [Related]
12. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
Massink MP; Kooi IE; Martens JW; Waisfisz Q; Meijers-Heijboer H
BMC Cancer; 2015 Nov; 15():877. PubMed ID: 26553136
[TBL] [Abstract][Full Text] [Related]
14. [Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
Nasedkina TV; Gromyko OE; Emel'ianova MA; Ignatova EO; Kazubskaia TP; Portnoĭ SM; Zasedatelev AS; Liubchenko LN
Mol Biol (Mosk); 2014; 48(2):243-50. PubMed ID: 25850293
[TBL] [Abstract][Full Text] [Related]
15. Comparing breast cancer imaging characteristics of CHEK2 with BRCA1 and BRCA2 gene mutation carriers.
Ghunaim H; Laenen A; De Keyzer F; Soens J; Keupers M; Postema S; Neven P; Van Ongeval C
Eur J Radiol; 2022 Jan; 146():110074. PubMed ID: 34902667
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel BRCA2 and CHEK2 A-C-G-C haplotype in Turkish patients affected with breast cancer.
Haytural H; Yalcinkaya N; Akan G; Arikan S; Ozkok E; Cakmakoglu B; Yaylim I; Aydin M; Atalar F
Asian Pac J Cancer Prev; 2013; 14(5):3229-35. PubMed ID: 23803109
[TBL] [Abstract][Full Text] [Related]
17. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR
Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers.
Toss A; Tenedini E; Piombino C; Venturelli M; Marchi I; Gasparini E; Barbieri E; Razzaboni E; Domati F; Caggia F; Grandi G; Combi F; Tazzioli G; Dominici M; Tagliafico E; Cortesi L
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33919281
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
20. High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia.
Sokolenko AP; Iyevleva AG; Preobrazhenskaya EV; Mitiushkina NV; Abysheva SN; Suspitsin EN; Kuligina ESh; Gorodnova TV; Pfeifer W; Togo AV; Turkevich EA; Ivantsov AO; Voskresenskiy DV; Dolmatov GD; Bit-Sava EM; Matsko DE; Semiglazov VF; Fichtner I; Larionov AA; Kuznetsov SG; Antoniou AC; Imyanitov EN
Int J Cancer; 2012 Jun; 130(12):2867-73. PubMed ID: 21815139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
